AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Shared Decision Making in Patients With Lung Cancer

Recruitingn/aAges 18 Years - anyAllSichuan Cancer Hospital and Research Institute
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The objective of this study is to develop a Decision Aid for Lung Cancer Molecular Testing (DA\_LCMT) and to facilitate shared-decision making in patients who were diagnosed with lung adenocarcinoma by intraoperative frozen pathology about whether to conduct the molecular testing.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion criteria: Patients of decision-making need assessment: 1\) age โ‰ฅ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have or have not made a decision on lung cancer molecular testing (whether to perform molecular testing or not). Other stakeholders of decision-making need assessment: 1\) age โ‰ฅ 18 years; 2) relevant work experience โ‰ฅ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process. Patients of Cognitive debriefing/Alpha tests: 1\) age โ‰ฅ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have made a decision on whether to perform lung cancer molecular testing or not. other stakeholders of Cognitive debriefing/Alpha tests: 1\) age โ‰ฅ 18 years; 2) relevant work experience โ‰ฅ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process. Patients of field testing /Beta tests: 1\) age โ‰ฅ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have not decided whether to perform lung cancer molecular testing or not. Clinician of field testing /Beta tests: 1\) age โ‰ฅ 18 years; 2) relevant work experience โ‰ฅ 2 years; 3) previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; and 4) voluntarily participated in this study. Exclusion criteria: Inability to understand the research content.
๐Ÿ’Š

What it tests

  • Qualitative interviews
๐Ÿ“

Where

1 site
Sichuan Cancer Hospital & Institute
Chengdu, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy